Xuli
Wang‡
*a,
Ye
Yang‡
b,
Huizhen
Jia
c,
Wanjian
Jia
a,
Scott
Miller
a,
Beth
Bowman
a,
Jun
Feng
*c and
Fenghuang
Zhan
*b
aDivision of Radiobiology, School of Medicine, University of Utah, 729 Arapeen Drive, Rm 2334, Salt Lake City, 84108, USA. E-mail: xuli.wang@utah.edu
bDepartment of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplant, University of Iowa, Iowa City, IA 52242, USA. E-mail: fenghuang-zhan@uiowa.edu
cKey Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, China. E-mail: fengjun@whu.edu.cn
First published on 14th April 2014
To improve bone metastasis chemotherapy, a peptide-conjugated diblock copolymer consisting of a chimeric peptide, poly(ethylene glycol) and poly(trimethylene carbonate) (Pep-b-PEG-b-PTMC) is fabricated as a drug carrier capable of bone-seeking as well as pathology-responsive charge reversal to ensure effective cellular uptake at the lesion sites. The chimeric peptide CKGHPGGPQAsp8 consists of an osteotropic anionic Asp8, a cathepsin K (CTSK)-cleavable substrate (HPGGPQ) and a cationic residue tethered to the polymer chain. Pep-b-PEG-b-PTMC can spontaneously self-assemble into negatively charged nanomicelles (∼75 nm). As to the model drug of doxorubicin, Pep-b-PEG-b-PTM shows 30.0 ± 1% and 90.1 ± 2% for the loading content and loading efficiency, respectively. High bone binding capability is demonstrated with 66% of Pep-b-PEG-b-PTMC micelles were able to bind to hydroxyl apatite, whereas less than 15% of Pep-free micelles were bound to hydroxyl apatite. The nanomicelles exhibit a negative-to-positive charge conversion from −18.5 ± 1.9 mV to 15.2 ± 1.8 mV upon exposure to CTSK, an enzyme overexpressed in bone metastatic microenvironments. Such a pathology-responsive transition would lead to remarkably enhanced cellular uptake of the nanomicelles upon reaching lesion sites, thus improving the drug efficacy as verified by the in vitro cytotoxicity assay and the in vivo study with the myeloma-bearing 5TGM1 mice model.
The surface decoration of drug nanovehicles (NVs) with bone-targeting moieties is among the most used strategies to improve the chemotherapy against bone metastases.5 Given the remarkable feature of skeletal tissue rich in apatite (Ca10(PO4)6), many anionic agents with high apatite binding affinity including bisphosphonates (BPs) and oligopeptides (Asp6, Asp8 and Glu8) have been purposely incorporated into NVs for the sake of bone-seeking action.5–7 However, the treatment efficacies achieved by those bone-targeting NVs are still far from satisfactory; some of them were even less efficacious than the unmodified counterparts. The marked deviation from the expectation is thought to be associated with the dilemma that the attachment of anionic agents to NVs inevitably restricts cellular translocation due to the charge repulsion by the cell membranes.4–6 In turn it is difficult for the drugs loaded into NVs to enter cancerous cells to elicit therapeutic action. In contrast, despite the easy intracellular internalization, the applications of positively charged NVs suffer a lot from rapid in vivo clearance and non-specific uptake by healthy tissues resulting from the strong interaction with oppositely charged blood components and the cell membranes. Taking those into account, the solution to bone-targeted chemotherapy may eventually rely on the rational design of anionic bone-seeking NVs which are simultaneously capable of undergoing negative-to-positive charge transition that mostly occurs in bone metastatic sites.
One notable physicochemical feature of bone metastases is the predominant over-expression of several proteases including matrix metalloproteinase, urokinase plasminogen activator, and cathepsins (cathepsins K, L, and B).8 In particular, the development of cancer metastases in bones is found to be highly correlated with the expression level of the acid-activated cathepsin K enzyme (CTSK). The bone metastatic lesions express even dramatically higher level of CTSK compared to primary tumor and soft tissue metastases.9 The strong dependence of bone metastases on the CTSK level makes CTSK able to serve as a prognostic indicator for the diagnosis of bone metastases and as a therapeutic target for disease treatments.10–12 This pathology-dependent feature of CTSK overexpression evokes our interest to exploit CTSK as the biological stimulus to locally trigger the charge reversal of anionic bone-seeking NVs upon reaching bone metastatic sites.13–16
We have herein designed a bone-seeking, CTSK-responsive charge-reversal NV system for efficient chemotherapy of bone metastases. This delivery system was constructed on the core–shell nanomicelles self-assembled from a triblock copolymer (Pep-b-PEG-b-PTMC) composed of a peptide segment with the sequence CKGHPGGPQAsp8, poly(ethylene glycol) and poly(trimethylene carbonate). The chimeric peptide segment consisted of three main functional modules: the anionic Asp8 is responsible for the direction and accumulation of NVs into the skeletal tissues, the HPGGPQ serves as the CTSK-cleavable substrate,8 and the remaining cationic residue is chemically conjugated to the PEG shell of the micelles. In this way, the combination of the targeting function of Asp8 and the stealth effect of the PEG shell would help the drug-loaded Pep-b-PEG-b-PTMC nanomicelles prolong the circulation time and minimize the undesirable cellular uptake by healthy cells. Of special note is that the bone metastatic microenvironment featured with CTSK overexpression would locally stimulate the enzymatic cleavage of HPGGPQ moieties, leaving the cationic peptide residue on the shell periphery. This pathology-responsive charge reversal transition is expected to largely contribute to the selectively efficient internalization of nanomicelles into the neighboring cancerous cells (Scheme 1), thus improving the therapeutic efficacy. In principle, this strategy of bone-seeking, pathology-responsive charge-reversal NVs may be also applicable to other malignant diseases of skeletal tissue if the development of those diseases involves overexpression of certain enzymes. To verify our hypothesis, an anticancer drug DOX was used as the drug model and the in vitro and in vivo properties of the Pep-b-PEG-b-PTMC nanomicelles were comparatively explored under the CTSK-rich and CTSK-absent conditions.
![]() | ||
Scheme 1 Schematic illustration of nanotherapeutic formation and its mechanism of action in vivo for bone metastasis treatment. |
The synthesis of a peptide-conjugated diblock copolymer of Pep-b-PEG-b-PTMC was based on the efficient click reaction between the cysteine terminated Pep peptide and the maleimidevinyl terminated Mal-PEG-b-PTMC diblock copolymer, as illustrated in Fig. 1. Via the well-established organocatalytic (i.e. TU) ring-opening polymerization approach, a non-functional MPEG-b-PTMC copolymer could be readily prepared with a defined molecular weight and narrow molecular distribution when using MPEG-OH (Mw = 5000 Da) as the macroinitiator.23 This strategy was problematic, however, when it came to the synthesis of the maleimide-terminated copolymer of Mal-PEG-b-PTMC starting from Mal-PEG-OH. 1H NMR analysis revealed that the maleimidevinylic protons at σ = 6.74 ppm in the product disappeared. Apparently, the maleimide group might be very labile to super basic conditions, and failed to remain intact during the polymerization process. Alternatively, the Mal-PEG110-b-PTMC52, in which 52 refers to the repeating units of TMC, was successfully synthesized under mild conditions under Sn(Oct)2 catalysis (Fig. 1A). 1H NMR analysis demonstrated that the maleimidevinylic protons at σ = 6.74 ppm in the product remained available after polymerization (Fig. 2). The copolymer composition and number-averaged molecular weight of Mal-PEG110-b-PTMC52 were determined from the integral ratio of PTMC protons at σ = 4.21 ppm versus that of the PEG proton at σ = 3.64 ppm. For comparison purposes, the peptide-free methoxy-terminated MPEG113-b-PTMC50 was also prepared.
![]() | ||
Fig. 1 Synthetic procedure and chemical structure of Mal-PEG110-b-PTMC52 (A), the Pep peptide (B) and Pep-b-PEG110-b-PTMC52 (C). |
![]() | ||
Fig. 2 1H NMR spectra of MPEG113-b-PTMC50 (CDCl3), Mal-PEG110-b-PTMC52 (CDCl3) and Pep-b-PEG110-b-PTMC52 (DMSO-d6). |
Next, we synthesized the functional peptide with a specially designed sequence of CKGHPGGPQAsp8 based on the solid phase peptide synthesis (SPPS) technique (Fig. 1B). The purity (98%) and molecular weight (calculated: 1800.64, found: 1800.54) of the target peptide were confirmed by high-performance liquid chromatography (HPLC) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, respectively (Fig. S1†). Via click chemistry, the chemical conjugation of CKGHPGGPQAsp8 to Mal-PEG110-PTMC52 afforded the target copolymer PEP-b-PEG110-b-PTMC52 (Fig. 1C), which was purified by the dialysis method (MWCO = 10 kDa) followed by ultrafiltration treatment. Successful conjugation was verified by 1H NMR, which clearly showed the characteristic resonances of the peptide protons at σ = 3.1–3.6 ppm and complete disappearance of the maleimidevinylic signal at σ = 6.74 ppm (Fig. 2).
As expected, Pep-b-PEG-b-PTMC could readily self-assemble into the micelles in aqueous solution like many other amphiphilic copolymers,24 which was confirmed by the fluorescence assay using pyrene as the probe. According to the excitation spectra of pyrene at different polymer concentrations, the critical micelle concentration (CMC) of Pep-b-PEG110-b-PTMC52 was determined to be approximately 8.02 × 10−3 mg mL−1 (Fig. 3C). The mean hydrodynamic diameter of the polymeric micelles was measured by dynamic light scattering (DLS) to be 75 ± 10 nm, showing unimodal size distribution with PDI ∼ 0.1.
![]() | ||
Fig. 3 1H NMR spectra of Pep-b-PEG110-b-PTMC52 in DMSO-d6 (A) and D2O (B); CMC measurement by plotting of the I340/I338 ratio against the logarithm of the polymer concentration (C). |
In principle, the hydrophobic PTMC segments should localize in the inner core of nanomicelles while the peptide and PEG blocks form a corona-type shell due to their highly hydrophilic nature. This core–shell structure was verified by the marked difference between its 1H NMR spectra in DMSO (Fig. 3A) and D2O (Fig. 3B). All the characteristic signals could be detectable in DMSO-d6. Unlike this, the proton signals of the PTMC block were significantly suppressed and nearly disappeared in aqueous D2O but those from hydrophilic blocks remained prominent. Taken together, those characterizations demonstrated that Pep-b-PEG110-b-PTMC52 was able to readily form the NVs with the core–shell architecture in the aqueous medium.
The strong binding ability of Pep-b-PEG110-b-PTMC52 micelles to hydroxyapatite (HA), commonly used as a model mineral to mimic the bone tissue mineral, was examined to preliminarily evaluate the contribution of the peptide functionality to the bone-seeking efficacy.5–7 A near infra-red fluorescence (NIRF) Cy5.5 probe has been one of the frequently used fluorescence indicators due to its deeper tissue penetration capacity.25 Cy5.5 was encapsulated into the micellar cores by the dialysis method thus to quantitatively determine the binding affinities of the nanomicelles with and without the peptide functionality.
After incubation for 30 min, approximately 55% of the Pep-b-PEG-b-PTMC micelles from the solution were rapidly bound to HA. Further incubation for 24 hours led to a moderate increase of HA-binding up to about 66% (Fig. 4). In marked contrast, less than 15% of MPEG-b-PTMC micelles or free Cy5.5 were bound to HA across the entire incubation process, indicating minimal nonspecific binding to HA by the MPEG-b-PTMC micelles without the peptide functionality. The low-molecular-weight peptide-Cy5.5 conjugate exhibited a much stronger affinity to HA with complete binding after incubation for 30 min. Those results correlated well with the reported findings that modification with osteotropic Asp8 would dramatically facilitate the specific binding towards HA-rich bone tissue.26–28 Though the outer PEG shell with steric hindrance may somewhat restrain the complete binding of Pep-b-PEG-b-PTMC micelles to HA, they still displayed dramatically enhanced HA affinities over Pep-free MPEG-b-PTMC micelles after all.
Typically, the decoration of bone-targeting anionic Asp8 to NVs would disfavor the cellular uptake process due to the charge repulsion by the cell membrane, thus impairing the chemotherapy efficacy.29 Within the structure of Pep-b-PEG-b-PTMC, a CTSK cleavable substrate (HPGGPQ)25,30 was specially incorporated to link Asp8 and the rest of the block copolymer. By virtue of such a CTSK-cleavable spacer, it was speculated that the bone metastatic microenvironment featured with CTSK overexpression would induce the enzymatic chain cleavage and the following removal of Asp8 moieties from the shell periphery of the nanomicelles. Of particular interest, this CTSK-induced transition may reverse the surface charge and thus enhance the cellular uptake of the nanomicelles, which was attributed to the remaining cationic peptide residues after Asp8 removal. To verify this speculation, the zeta potentials of polymeric micelles were measured in the presence and absence of CTSK, respectively. Following 30 min treatment with CTSK, the zeta potential of Pep-b-PEG-b-PTMC micelles had an instantly marked promotion from −18.5 ± 1.9 mV to 15.2 ± 1.8 mV (Fig. 5). Nevertheless, the control experiment without CTSK treatment afforded nearly no variation of the zeta potential. Apparently, it is just CTSK exposure that allowed the charge reversal of the Pep-b-PEG-b-PTMC micelles.
![]() | ||
Fig. 5 Change in the zeta potential of Pep-b-PEG-b-PTMC micelles upon co-incubation with 150 nM CTSK for 30 minutes. |
For comparison, the CTSK-responsiveness of the zeta potential was also tested for MPEG-b-PTMC micelles with the identical CTSK treatment. No apparent variation was found upon CTSK exposure and the micellar zeta potential remained almost constant within a narrow range from −8.6 ± 2.1 mV to −8.4 ± 0.7 mV. Those results pointed out that the introduction of the CKGHPGGPQAsp8 functionality indeed played a dominant role in the CTSK-induced negative-to-positive charge conversion of Pep-b-PEG-b-PTMC micelles.
To evidence the contribution of CTSK-responsive charge reversal to the intracellular internalization, confocal laser scanning microscopy (CLMS) was used to investigate the cellular uptake of polymeric micelles under the conditions with or without CTSK treatment. The nanomicelles assembled from Pep-b-PEG-b-PTMC were loaded with the Cy5.5 fluorescence indicator, followed by incubation with MCF-7 cells in the presence or absence of CTSK. Following 30 min incubation, the MCF-7 cells were subjected to CLMS observation. As shown in Fig. 6, very weak red fluorescence can be detected in the cells co-incubated with Pep-b-PEG-b-PTMC micelles in the medium free of CTSK, indicating that few fluorescence-labeled micelles were taken up by MCF-7 cells under this condition. The poor cellular uptake of untreated micelles was reasonably expected, because it was difficult for the negatively charged NVs to be intracellularly internalized owing to the charge repulsion effect. However, upon CTSK exposure, significant fluorescence enhancement was observed from the CLSM images. This was ascribed to the cationic nature of the micelles resulting from CTSK-induced charge-reversal, which was known to favor the approach of NVs to the negatively charged cell membranes and thus facilitate their cellular uptake. For the control of MPEG-b-PTMC micelles, it is not strange that a minimal difference was observed between the CLSM images obtained before and after CTSK treatment (data not shown).
![]() | ||
Fig. 6 CLSM images of MCF-7 cells incubated with Pep-b-PEG-b-PTMC micelles with or without CTSK treatment. |
The CTSK-dependent cellular uptake of Pep-b-PEG-b-PTMC nanomicelles seemed very attractive in terms of the chemotherapy potential for bone metastases. It can be noted that those nanomicelles would be hardly taken up by the cells in the normal tissues due to the lack of CTSK expression; once the nanoparticles were guided and accumulated in CTSK-rich environments (i.e., CTSK over-expressed bone metastases lesions), however, the transition to cationic NVs would considerably facilitate the entry into the neighboring tumor cell and thus allow the effective treatment with lower systematical biotoxicity.
To further explore the potential of Pep-b-PEG-b-PTMC as a drug carrier, an anticancer drug DOX was used as a model drug to investigate the drug loading and release properties. Poorly water-soluble DOX was encapsulated into the micelles of Pep-b-PEG-b-PTMC or MPEG-b-PTMC by the dialysis method. Typical DOX-loading capacity for mPEG-b-PTMC micelles was determined as 7.5 ± 0.5% and 22.7 ± 1.5% for DLC (drug loading content) and DLE (drug loading efficiency), respectively. Dramatic increases of DLC (30.0 ± 1%) and DLE (90.1 ± 2%) were observed when Pep-b-PEG-b-PTMC was used as the drug carrier. Such a high loading efficiency may be the result of the charged nature of Pep-b-PEG-b-PTMC, for which the outer PEG chains extend more freely and more aggregation numbers per micelle are required to ensure the hydrophilic–hydrophobic balance in the aqueous medium. Thus the DOX drug molecules enter the micelle interior more readily and the larger core is more capable of containing more drug cargos. This is consistent with the finding reported in the literature that charged NVs generally possess high DOX-loading capacity.13,31–33 The representative example is that the highest drug loading (47% w/w) of DOX-loaded micelles reported to date was achieved when anionic polymeric glutamic acid (PGA) was used as a building block within PTMC-b-PGA.31 The in vitro drug release study was performed under a simulated physiological condition (pH 7.4). Fig. 7A compares the drug release profiles between the free DOX and the DOX loaded in Pep-b-PEG-b-PTMC micelles. The results suggested that DOX-loaded micelles exhibited a moderately rapid release in the first stage (around 10%) followed by a sustained release period. The sustained DOX release could be attributed to the hydrophobic interaction of drug molecules with the hydrophobic core of the polymeric micelles.
The in vitro cytotoxicity profiles of free DOX or DOX-loaded polymeric micelles were evaluated in the cultured cells including myeloma (the most frequent cancer type for bone metastases) suspension cell lines (5TGM1 and ARP-1) and a breast cancer (the second most frequent cancer type for bone metastases) adherent cell line (MCF-7) by the PrestoBlue™ (Invitrogen) assay. The PrestoBlue assay performed very well to quantitatively measure cell proliferation and to establish the relative viability of both suspension and adherent cells. As shown in Fig. 7C, free DOX exhibited a relatively higher toxic effect than that of both DOX-loaded Pep-free and Pep-functionalized polymeric micelles after 4 h culture. The lowered potency of DOX after encapsulation into the micelles was probably due to the sustained release pattern of DOX from the micelles and delayed drug efficacy in the cultured cells. Overall, DOX-loaded Pep-PEG-b-PTMC nanomicelles showed lower cytotoxicity than the Pep-free MPEG-b-PTMC micelles. Since the CTSK activity has strong association with the interactions between tumor cells and the bone microenvironment, to give more exact information about the influence of CTSK-responsive charge-reversal on the biological properties of Pep-b-PEG-b-PTMC micelles, the 5TGM1 cytotoxicity of the DOX-loaded micelles was comparatively explored after a short co-incubation period of 30 min under the conditions with or without CTSK treatment. At an equivalent DOX dose (1 μg mL−1), drug-loaded Pep-b-PEG-b-PTMC micelles showed lower capability to induce the cell death than the Pep-free MPEG-b-PTMC control. CTSK treatment resulted in significant improvement of the drug efficacy in the case of Pep-b-PEG-b-PTMC micelles (Fig. 7B), which was even comparable to the acute toxicity of free DOX. Noticeably, the CTSK-responsive improvement of toxic effect was not observed for free DOX or DOX-loaded mPEG-b-PTMC micelles. This marked contrast manifested a close tie between the CTSK responsiveness and the Pep functionality in the micelles, which contributed much to the enhanced drug efficacy. In combination with the result of intracellular internalization obtained from confocal images, it is naturally inferred that the anionic nature associated with the targeting Asp8 moieties would disfavor the intracellular internalization of the Pep-b-PEG-b-PTMC micelles and therefore impair the drug efficacy, whereas CTSK-responsive charge reversal may more or less overcome this biological barrier.
Despite the advance of drug delivery nanosystems for bone metastases, to the best of our knowledge, nearly no in vivo efficacy evaluation in animal studies have yet been reported. This could be in part ascribed to the limited availability of suitable detection means for the disease progression of bone metastases. Herein, a preliminary in vivo study was conducted to test the efficacy of DOX-loaded Pep-b-PEG-b-PTMC nanomicelles in a 5TGM1-induced myeloma-bearing mice model. Multiple myeloma is the most frequent cancer-induced osteolytic disease,1,2 which intends to invade skeletal tissues in a similar mechanism to cancer cells that interact with the bone marrow microenvironment.34 Likewise, the interactions between myeloma cells and osteoclasts yield substantial cathepsin K up-regulation, resulting in osteolytic lesions.35 Noticeably, the real-time tumor burden in 5TGM1 mice can be easily monitored by measuring the 5TGM1 idiotype (IgG2b) in mouse sera.36 The higher IgG2b level in sera, the bigger tumor in the body. This is a distinct advantage since the progression of other types of cancers can only be identified with advanced imaging modalities (μCT, X-ray, etc.).37 Myeloma-bearing 5TGM1 mice were established through inoculation of 5TGM1 cells (1 × 106 cells in 100 μL PBS) via tail veil injection, and the tumors were allowed to develop and grow for one week before initiating study treatments. The mice were injected twice weekly with different therapeutic formulations at an equivalent DOX dose (0.75 mg kg−1) or blank PBS, and the IgG2b level in sera was monitored by ELISA measurements.
As shown in Fig. 8A, the myeloma-bearing 5TGM1 mice group treated with DOX-loaded Pep-b-PEG-b-PTMC micelles showed prolonged survival rate in comparison with the control groups with the administration of DOX-loaded MPEG-b-PTMC micelles, free DOX or blank PBS. Since the tumor burden was positively correlated with the IgG2b level, the data in Fig. 8B distinctly indicated that Pep-b-PEG-b-PTMC/DOX nanotherapeutic was meanwhile more effective to slow down tumor growth than the other formulations with the equivalent DOX dose. Together with the in vitro results, the observed improvement of both in vivo systematic biosafety and drug efficacy manifested the superiority of our pathology-specific design by combining both the advantages of efficient DOX delivery to bone metastatic tissues and CTSK-responsive cellular uptake of DOX within lesion sites.
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c4bm00020j |
‡ These authors contributed equally. |
This journal is © The Royal Society of Chemistry 2014 |